Survival among elderly metastatic breast cancer patients in the United States.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e16500-e16500
Author(s):  
K. L. Davis ◽  
S. Iyer ◽  
S. Candrilli
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
The United States ◽  
Breast Cancer Patients

scholarly journals IL-6 is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Messenger Rna ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
The United States ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified the cytokine interleukin-6 (IL-6) (5) as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of IL-6 messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of IL-6 in primary tumors of the breast, suggesting that increased primary tumor expression of IL-6 in the primary tumors of patients with breast cancer, a cytokine whose serum levels are correlated with worse patient survival outcomes in metastatic breast cancer (6), is a direct transcriptional result of treatment with trastuzumab.

Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18617-e18617
Author(s):  
Adriana Reis Brandao Matutino ◽  
Allan Andresson Lima Pereira ◽  
Elizabeth Kornaga ◽  
Sasha M. Lupichuk ◽  
Sunil Verma
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Metastatic Breast ◽  
Insurance Status ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document